Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Approvals Drug Review

EMA: Moment Of Truth For Two Curative Therapies & A Possible Cholesterol-Lowering Blockbuster

  • News

Executive Summary

The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.

You may also be interested in...



BioMarin Pulls EU Hemophilia Gene Therapy Filing, But Is Not Giving Up

BioMarin plans to resubmit its marketing application for Roctavian to the European Medicines Agency.

Bayer Seeks Speedy EMA Review For Diabetic Kidney Disease Drug Finerenone

The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.

As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran

Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip

Topics

Related Companies

Tags:
Europe Approvals Drug Review
Latest Headlines

Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?

Coronavirus Notebook: UN Pandemic Declaration Disappoints, Focus Turns To Draft WHO Treaty

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

See All
UsernamePublicRestriction

Register

PS143094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By